Denosumab and changes in bone turnover markers during androgen deprivation therapy for prostate cancer

Biochemical markers of bone turnover and clinical outcomes in men with prostate cancer

(2010) Fred Saad et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

Biochemical Markers of Bone Turnover, Hip Bone Loss, and Fracture in Older Men: The MrOS Study

(2009) Douglas C Bauer et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Effects of denosumab in patients with bone metastases with and without previous bisphosphonate exposure

(2009) Jean-Jacques Body et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Denosumab in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer

(2009) Matthew R. Smith et al.   NEW ENGLAND JOURNAL OF MEDICINE

Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis

(2009) Steven R. Cummings et al.   NEW ENGLAND JOURNAL OF MEDICINE

Bone turnover markers: understanding their value in clinical trials and clinical practice

(2009) R. Civitelli et al.   OSTEOPOROSIS INTERNATIONAL

Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: A randomized blinded phase 2 clinical trial

(2008) Paul D. Miller et al.   BONE

Skeletal Health After Continuation, Withdrawal, or Delay of Alendronate in Men With Prostate Cancer Undergoing Androgen-Deprivation Therapy

(2008) Susan L. Greenspan et al.   JOURNAL OF CLINICAL ONCOLOGY

Managing Bone Loss in Men With Locally Advanced Prostate Cancer Receiving Androgen Deprivation Therapy

(2008) Ron S. Israeli et al.   JOURNAL OF UROLOGY